Northwest Biotherapeutics Inc (NWBO) stock
NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)
Close on Oct 19, 2026Market cap $254.79MP/E –Yield –
Northwest Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Northwest Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $23.57M, down 31.6% year over year. For fiscal 2025 it was $28.79M, down 17.5% from the year before. Over ten years it grew -12.0% a year on average. The highest annual figure on record is $103.12M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.79M | -17.5% |
| FY2024 | Dec 31, 2024 | $34.89M | +25.8% |
| FY2023 | Dec 31, 2023 | $27.73M | -21.9% |
| FY2022 | Dec 31, 2022 | $35.51M | +74.9% |
| FY2021 | Dec 31, 2021 | $20.31M | -39.6% |
| FY2020 | Dec 31, 2020 | $33.64M | +138.5% |
| FY2019 | Dec 31, 2019 | $14.11M | -22.3% |
| FY2018 | Dec 31, 2018 | $18.15M | -45.8% |
| FY2017 | Dec 31, 2017 | $33.52M | -44.2% |
| FY2016 | Dec 31, 2016 | $60.08M | -41.7% |
| FY2015 | Dec 31, 2015 | $103.12M | +20.4% |
| FY2014 | Dec 31, 2014 | $85.64M | +95.0% |
| FY2013 | Dec 31, 2013 | $43.91M | +51.9% |
| FY2012 | Dec 31, 2012 | $28.91M | +114.9% |
| FY2011 | Dec 31, 2011 | $13.45M | +35.9% |
| FY2010 | Dec 31, 2010 | $9.90M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.71M | -23.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.86M | -41.8% |
| Q4 FY2025 | Dec 31, 2025 | $5.55M | -47.2% |
| Q3 FY2025 | Sep 30, 2025 | $7.45M | -8.4% |
| Q2 FY2025 | Jun 30, 2025 | $7.43M | -10.4% |
| Q1 FY2025 | Mar 31, 2025 | $8.35M | +5.1% |
| Q4 FY2024 | Dec 31, 2024 | $10.52M | +41.2% |
| Q3 FY2024 | Sep 30, 2024 | $8.13M | +12.9% |
| Q2 FY2024 | Jun 30, 2024 | $8.29M | +33.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.94M | +15.8% |
| Q4 FY2023 | Dec 31, 2023 | $7.45M | -20.3% |
| Q3 FY2023 | Sep 30, 2023 | $7.20M | -6.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.21M | -54.5% |
| Q1 FY2023 | Mar 31, 2023 | $6.86M | +42.3% |
| Q4 FY2022 | Dec 31, 2022 | $9.35M | +123.4% |
| Q3 FY2022 | Sep 30, 2022 | $7.69M | +105.3% |
| Q2 FY2022 | Jun 30, 2022 | $13.65M | +53.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.82M | -72.7% |
| Q4 FY2021 | Dec 31, 2021 | $4.19M | +30.0% |
| Q3 FY2021 | Sep 30, 2021 | $3.75M | -2.8% |
| Q4 FY2020 | Dec 31, 2020 | $8.90M | +121.7% |
| Q3 FY2020 | Sep 30, 2020 | $17.66M | +399.2% |
| Q2 FY2020 | Jun 30, 2020 | $3.22M | -2.2% |
| Q1 FY2020 | Mar 31, 2020 | $3.86M | +28.4% |
| Q4 FY2019 | Dec 31, 2019 | $4.01M | +4.4% |
| Q3 FY2019 | Sep 30, 2019 | $3.54M | -17.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.29M | -37.7% |
| Q1 FY2019 | Mar 31, 2019 | $3.00M | -36.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.84M | -71.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.30M | -74.5% |
| Q2 FY2018 | Jun 30, 2018 | $5.28M | -75.0% |
| Q1 FY2018 | Mar 31, 2018 | $4.73M | -45.7% |
| Q4 FY2017 | Dec 31, 2017 | $13.29M | -1.1% |
| Q4 FY2016 | Dec 31, 2016 | $16.83M | -63.8% |
| Q3 FY2016 | Sep 30, 2016 | $21.09M | – |
| Q2 FY2016 | Jun 30, 2016 | $8.71M | – |
| Q1 FY2016 | Mar 31, 2016 | $13.44M | – |
| Q4 FY2015 | Dec 31, 2015 | $46.56M | – |
See a number that looks wrong?